Efficacy of a Rhealba ® Oat Extract‐based emollient on chronic pruritus in elderly French outpatients

Background Inflammation from skin conditions such as psoriasis, eczema‐like atopic dermatitis (AD) and hand eczema (HE) and following dermatological procedures (post‐acts) can result in intense itching and cutaneous pain. Dermo‐cosmetics containing plant extracts have been shown to reduce or alleviate these symptoms. Objectives Assessment of the tolerability and efficacy of a spray containing Rhealba\xAE Oat plantlets and Uncaria tomentosa extracts in adults and children with inflammatory skin diseases and after dermatological procedures. Methods Data from five open label studies were analysed (Study 1: adults with AD; Study 2: children with AD; Study 3: adults with psoriasis; Study 4: adults with HE; Study 5: adults who had undergone a dermatological procedure: laser, intense pulsed light, glycolic acid peeling, photodynamic therapy or cryotherapy procedure). In all studies, subjects could use the test product up to six times per day for symptom relief. Physical and functional signs of inflammation, treatment‐emergent adverse events (TEAEs), soothing effect, changes in quality of life, cutaneous pain and cosmetic acceptability were compared pre‐ and postapplication. Results A total of 176 subjects were enrolled across the five studies. Overall, investigators judged the dermatological tolerance of the test product containing Rhealba\xAE Oat plantlets extract and Uncaria tomentosa as good to excellent. All studies showed significant improvements in physical signs, reduction in itching and feeling of pain (P < 0.05). The soothing effect was evident after the first application. TEAEs were mostly mild, transient and occurred within the first few days of treatment. The majority of subjects reported improved QoL across the studies. Conclusions The dermo‐cosmetic spray containing Rhealba\xAE Oat plantlets extract and U. tomentosa was well tolerated and efficacious in providing relief of symptoms associated with cutaneous pain from inflammatory skin diseases and following dermatological procedures; however, further studies are needed to rule out alternative explanations of symptom reduction such as natural history and response biases.

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A spray containing extracts of oat plantlets and Uncaria tomentosa relieves pain associated with chronic inflammatory skin diseases and dermatological procedures

Reich

Estebaranz

Bahadoran

et al. 2020

“…The Rhealba Oat plantlets extraction process is designed to release high levels of active principles such as flavonoids and saponins, without any protein to prevent patients from any sensitization effect . Rhealba Oat plantlets extract have anti‐inflammatory properties with efficacy in pruritus and thus efficacy in inflammatory dermatosis (atopic dermatitis, contact and irritant dermatitis, psoriasis).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of a repair cream based on Rhealba Oat plantlets extract and active healing compounds in peelings: benefit to patient's downtime and pain

Ocampo‐Candiani

Aroman

Carballido

et al. 2019

Background The frequency of dermatological procedures is steadily increasing, accompanying a growing demand from patients. Chemical peels are a method of resurfacing in the treatment of various skin conditions. However, during the early healing process, patients may impose downtime on themselves. The erythema, pain and poor aesthetic appearance of the skin can lead to unwillingness to participate in social or professional activities. Objectives The objective of this study was to evaluate the tolerance and efficacy of a repair cream based on Rhealba Oat plantlets extract and active healing compounds after a peeling procedure. Methods Men and women, aged 18–65 years, with Fitzpatrick phototype I‐IV, who had previously received a medium‐depth chemical peel on the face (TCA 30%) entered with their consent a clinical study evaluating the new test product based on Rhealba Oat and active healing compounds. At the beginning of the study, the selected patients received a TCA 30% medium‐depth peel. Afterwards, they were treated during 29 days with the repair cream and evaluated for the benefits to downtime and pain. Results Significant reductions of pain (P < 0.0114) and erythema (P < 0.0001) were observed in the study. The downtime reduction with the tested cream was 92% ‐ from 9 days after the previous peeling procedure to 0.74 days with application of the tested cream – a difference of 8.39 days. Conclusion In consequence, the tested repair cream based on Rhealba Oat plantlets extract and active healing compounds brings clinical benefit to patients who undergo peeling procedures. By reducing pain and downtime, it allows patients to get back to their daily life activities a week earlier than with previous peels.

“…Use of emollients reduces the requirement for topical corticosteroids, which is particularly beneficial in elderly patients, in whom they can cause further thinning of the skin as well as impairment of the immune response . The antipruritic effect of 2‐week treatment with a Rhealba Oat extract‐based emollient (Xeramega Confort ® , A‐Derma, Pierre Fabre) was demonstrated in a study involving 30 French outpatients aged ≥60 years with chronic pruritus . At the end of 2 weeks of treatment, more than half of the subjects reported an improvement in pruritus, and 30% reported complete disappearance, whereas pruritus remained stable during a 2‐week non‐treatment phase.…”

Section: From Paediatric To Geriatric Dermatology: Focus On Populatiomentioning

confidence: 99%

Dermatology today and tomorrow: from symptom control to targeted therapy

Blume-Peytavi

Bagot

Tennstedt

et al. 2018

Self Cite

For many decades and until recently, medical approach to dermatologic diseases has been based on the physician's ability to recognize and treat symptoms. Nowadays, advances in the understanding of the biology of diseases and in technologies for intervening against them have allowed physicians to diagnose and treat underlying disease processes rather than simply addressing the symptoms. This means that rather than addressing ‘the disease in humans’, physicians can now address the particular pathologic (biologic, molecular) disturbance as it presents in the individual patient, i.e., physicians now can practice something much closer to ‘personalized medicine’, leading to greater benefits for the patients and the health of society in general. The deeper understanding of ultraviolet radiation, the importance of photoprotection and increased knowledge about signalling pathways of melanoma and carcinoma have led to more complete care for the dermatologic patient. The current popularity for excessive exposure to the sun, without adequate application of the appropriate photoprotection remedies, is the origin of melanoma, but also for the weakening of the structure and functions of the skin. Indeed, fragility of the skin can affect humans around the world. In the senior population, this skin fragility is accompanied by pruritus, whereas atopic dermatitis is an inflammatory disease with highest prevalence in children and adolescents. Acne, the number one reason for dermatologic consultations worldwide, increases its prevalence in adolescents and in females. Senescent alopecia affects humans after menopause and andropause. The articles in this publication present an overview of the current advanced understanding of the diagnosis and therapeutic approaches in 6 fields of dermatology – dermatopaediatry and gerontodermatology, oncodermatology, hair loss, atopic dermatitis, photoprotection and acne – and thereby serve as a useful compendium of updated information and references for all healthcare professionals who see patients with presentations of the symptoms of these diseases.